Israel imposes first-ever excessive pricing fine
Shutterstock/Video_Creative
Israel’s Competition Authority has fined drug distributor MBI Pharma €2.2 million for abusing its dominance by charging unfairly high prices for a life-saving genetic disorder treatment drug, marking the enforcer’s first-ever excessive pricing infringement decision.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now